Asset

SOMATROGON

OPKO Health Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (8)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01909479phase3terminated2013-06-012016-08-01OPKO Health, Inc.A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
NCT02500316phase2completed2014-02-012023-11-01OPKO Health, Inc.Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT01225666phase2completed2010-08-012011-07-01OPKO Health, Inc.MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)
NCT01060722phase1completed2009-10-012010-01-01OPKO Health, Inc.MOD-4023 Study in Healthy Male Volunteers
NCT02418767phase1completed2015-01-012015-03-01OPKO Health, Inc.Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)